BTIG Maintains Buy on Exagen, Lowers Price Target to $8

Benzinga Newsdesk www.benzinga.com Negative 74.8%

Neg 74.8% Neu 0% Pos 0%

BTIG analyst Mark Massaro maintains Exagen (NASDAQ:XGN) with a Buy and lowers the price target from $9 to $8.

Comments

No comments yet. Be the first!